Logo image of IPH.PA

INNATE PHARMA SA (IPH.PA) Stock Fundamental Analysis

EPA:IPH - Euronext Paris - Matif - FR0010331421 - Common Stock - Currency: EUR

1.53  +0.01 (+0.53%)

Fundamental Rating

2

IPH gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 65 industry peers in the Biotechnology industry. IPH has a bad profitability rating. Also its financial health evaluation is rather negative. IPH is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IPH had negative earnings in the past year.
In the past year IPH has reported a negative cash flow from operations.
IPH had negative earnings in each of the past 5 years.
In the past 5 years IPH always reported negative operating cash flow.
IPH.PA Yearly Net Income VS EBIT VS OCF VS FCFIPH.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

1.2 Ratios

With a Return On Assets value of -44.54%, IPH is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
IPH's Return On Equity of -560.01% is on the low side compared to the rest of the industry. IPH is outperformed by 70.77% of its industry peers.
Industry RankSector Rank
ROA -44.54%
ROE -560.01%
ROIC N/A
ROA(3y)-25.61%
ROA(5y)-23.47%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
IPH.PA Yearly ROA, ROE, ROICIPH.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IPH.PA Yearly Profit, Operating, Gross MarginsIPH.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

IPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IPH has more shares outstanding
Compared to 5 years ago, IPH has more shares outstanding
Compared to 1 year ago, IPH has a worse debt to assets ratio.
IPH.PA Yearly Shares OutstandingIPH.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IPH.PA Yearly Total Debt VS Total AssetsIPH.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -4.90, we must say that IPH is in the distress zone and has some risk of bankruptcy.
IPH has a worse Altman-Z score (-4.90) than 69.23% of its industry peers.
A Debt/Equity ratio of 8.02 is on the high side and indicates that IPH has dependencies on debt financing.
The Debt to Equity ratio of IPH (8.02) is worse than 70.77% of its industry peers.
Industry RankSector Rank
Debt/Equity 8.02
Debt/FCF N/A
Altman-Z -4.9
ROIC/WACCN/A
WACC6.95%
IPH.PA Yearly LT Debt VS Equity VS FCFIPH.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

IPH has a Current Ratio of 2.60. This indicates that IPH is financially healthy and has no problem in meeting its short term obligations.
IPH has a Current ratio (2.60) which is comparable to the rest of the industry.
A Quick Ratio of 2.60 indicates that IPH has no problem at all paying its short term obligations.
IPH has a Quick ratio of 2.60. This is in the better half of the industry: IPH outperforms 61.54% of its industry peers.
Industry RankSector Rank
Current Ratio 2.6
Quick Ratio 2.6
IPH.PA Yearly Current Assets VS Current LiabilitesIPH.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

IPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -549.63%.
The Revenue for IPH has decreased by -75.68% in the past year. This is quite bad
Measured over the past years, IPH shows a very negative growth in Revenue. The Revenue has been decreasing by -28.80% on average per year.
EPS 1Y (TTM)-549.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-163.49%
Revenue 1Y (TTM)-75.68%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-73.85%

3.2 Future

Based on estimates for the next years, IPH will show a very negative growth in Earnings Per Share. The EPS will decrease by -14.00% on average per year.
The Revenue is expected to grow by 43.06% on average over the next years. This is a very strong growth
EPS Next Y121.73%
EPS Next 2Y75.86%
EPS Next 3Y-14%
EPS Next 5YN/A
Revenue Next Year86.96%
Revenue Next 2Y85.05%
Revenue Next 3Y29.35%
Revenue Next 5Y43.06%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IPH.PA Yearly Revenue VS EstimatesIPH.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
IPH.PA Yearly EPS VS EstimatesIPH.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 -0.6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IPH. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 17.21, the valuation of IPH can be described as rather expensive.
IPH's Price/Forward Earnings ratio is rather cheap when compared to the industry. IPH is cheaper than 87.69% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.70. IPH is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 17.21
IPH.PA Price Earnings VS Forward Price EarningsIPH.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IPH.PA Per share dataIPH.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
IPH's earnings are expected to decrease with -14.00% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y75.86%
EPS Next 3Y-14%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INNATE PHARMA SA

EPA:IPH (7/1/2025, 7:00:00 PM)

1.53

+0.01 (+0.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)09-17 2025-09-17
Inst Owners10.09%
Inst Owner ChangeN/A
Ins Owners2.18%
Ins Owner ChangeN/A
Market Cap141.00M
Analysts78.18
Price Target5.28 (245.1%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.23%
PT rev (3m)0.31%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)167.69%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 17.21
P/S 11.17
P/FCF N/A
P/OCF N/A
P/B 15.96
P/tB 15.96
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)0.09
Fwd EY5.81%
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0.14
BVpS0.1
TBVpS0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.54%
ROE -560.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.61%
ROA(5y)-23.47%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 8.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.61%
Cap/Sales 3.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.6
Quick Ratio 2.6
Altman-Z -4.9
F-Score1
WACC6.95%
ROIC/WACCN/A
Cap/Depr(3y)22.77%
Cap/Depr(5y)23.45%
Cap/Sales(3y)3.3%
Cap/Sales(5y)8.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-549.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-163.49%
EPS Next Y121.73%
EPS Next 2Y75.86%
EPS Next 3Y-14%
EPS Next 5YN/A
Revenue 1Y (TTM)-75.68%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-73.85%
Revenue Next Year86.96%
Revenue Next 2Y85.05%
Revenue Next 3Y29.35%
Revenue Next 5Y43.06%
EBIT growth 1Y-307.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year128.78%
EBIT Next 3Y30.44%
EBIT Next 5YN/A
FCF growth 1Y79.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y78.82%
OCF growth 3YN/A
OCF growth 5YN/A